CBRNE - Vesicants, Organic Arsenicals - L, ED, MD, PD, HL Follow-up

  • Author: Geoffrey M Fitzgerald, MD; Chief Editor: Robert G Darling, MD, FACEP   more...
 
Updated: Jun 3, 2011
 

Further Inpatient Care

  • Victims of severe toxicity from an organic arsenical may require prolonged care for dermatologic, ophthalmic, and pulmonary sequelae.
Next

Further Outpatient Care

  • Patients with only minor skin and eye lesions can be discharged with outpatient follow-up care.
Previous
Next

Complications

  • Permanent discoloration can occur at blister sites, especially with phenyldichloroarsine (PD).
  • Patients with mild conjunctival irritation can be expected to fully recover in 1-2 weeks. Patients with moderate conjunctival irritation with mild corneal damage can expect recovery in 4-6 weeks, but severe corneal damage may be irreversible, especially in phenyldichloroarsine (PD) exposure.
  • Victims who suffered mild-to-moderate pulmonary exposure can expect full recovery in 1-4 weeks. Severe vapor exposure can lead to permanent damage to the respiratory mucosa. This can lead to an increased risk of future infection and/or neoplasia. Secondary bacterial pneumonia is most common 3-6 days postexposure.
  • Victims with severe exposure to an organic arsenical can experience long-term complications in a number of organ systems, including neurologic, endocrine, and thermoregulatory disorders. The exact mechanism of these effects is unknown.
Previous
Next

Prognosis

  • Prognosis is good in all but the most severe cases.
Previous
Next

Patient Education

Previous
 
Contributor Information and Disclosures
Author

Geoffrey M Fitzgerald, MD  Consulting Staff, Concord Emergency Medical Associates

Disclosure: Nothing to disclose.

Coauthor(s)

Timothy Vollmer, MD  Consulting Staff, Department of Emergency Medicine, Geisinger Medical Center

Disclosure: Nothing to disclose.

Specialty Editor Board

Fred Henretig, MD  Director, Section of Clinical Toxicology, Professor, Medical Director, Delaware Valley Regional Poison Control Center, Departments of Emergency Medicine and Pediatrics, University of Pennsylvania School of Medicine, Children's Hospital

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Rick Kulkarni, MD 

Rick Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: WebMD Salary Employment

John D Halamka, MD, MS  Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center

John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Chief Editor

Robert G Darling, MD, FACEP  Adjunct Clinical Assistant Professor of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Associate Director, Center for Disaster and Humanitarian Assistance Medicine

Robert G Darling, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, American Telemedicine Association, and Association of Military Surgeons of the US

Disclosure: Nothing to disclose.

References
  1. Devereaux A, Amundson DE, Parrish JS. Vesicants and nerve agents in chemical warfare. Decontamination and treatment strategies for a changed world. Postgrad Med. Oct 2002;112(4):90-6; quiz 4. [Medline].

  2. Comptom JA. The arsenicals. In: Military Chemical and Biological Agents: Chemical and Toxicological Properties. 1987:17-43.

  3. Ford MD. Metal and metalloids. In: Emergency Medicine: A Comprehensive Study Guide. 5th ed. 2000:1185-1191.

  4. Ford MD. Arsenic. In: Goldfrank's Toxicology Emergencies. 6th ed. 1998:1261-1270.

  5. Karalliedde L, Wheeler H, Maclehose R, Murray V. Possible immediate and long-term health effects following exposure to chemical warfare agents. Public Health. Jul 2000;114(4):238-48. [Medline].

  6. NATO. Blistering agents. In: Emergency War Surgery NATO Handbook. 2nd US revision. 1988:88-90.

  7. Sidell FR, Urbanetti JS, Smith WJ. Vesicants. In: Medical Aspects of Chemical and Biological Warfare. 1997:197-228.

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.